EI
URGN icon

Ellevest Inc’s UroGen Pharma URGN Stock Holding History

Ellevest Inc’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-43
Closed -$397 – 1562
2023
Q1 		$397 Hold
43
– – ﹤0.01% 1700
2022
Q4 		$381 Sell
43
-24
-36% -$227 ﹤0.01% 1654
2022
Q3 		$1K Sell
67
-44
-40% -$364 ﹤0.01% 1532
2022
Q2 		$1K Sell
111
-395
-78% -$2.71K ﹤0.01% 1329
2022
Q1 		$4K Buy
506
+356
+237% +$2.78K ﹤0.01% 1101
2021
Q4 		$1K Sell
150
-12
-7% -$169 ﹤0.01% 1336
2021
Q3 		$3K Buy
162
+86
+113% +$1.36K ﹤0.01% 1087
2021
Q2 		$1K Buy
76
+42
+124% +$759 ﹤0.01% 1212
2021
Q1 		$1K Buy
+34
New +$722 ﹤0.01% 1209

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Ellevest Inc's URGN Position: Q2 2023 in Review

Ellevest Inc sold out of UroGen Pharma (URGN) in Q2 2023, closing a stake of 43 shares — an estimated $397 sold.

Ellevest Inc first reported a position in URGN in Q1 2021 and held it in 9 quarters. The position peaked at $4K in Q1 2022. 85 funds tracked by Wall St. Rank hold URGN as of Q2 2023.

  • Ellevest Inc reported no remaining UroGen Pharma position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 43 UroGen Pharma shares in Q2 2023, an estimated $397.
  • Ellevest Inc first reported a position in UroGen Pharma in Q1 2021 and held it in 9 quarters.
  • Ellevest Inc's UroGen Pharma position peaked at $4K in Q1 2022.
  • 85 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.